

CURRICULUM VITAE ROSA MARIA MORESCO

Place of Birth: Milan, Italy

Date of Birth: 26 December 1963

Work address: Università di Milano-Bicocca, Dipartimento Medicina e Chirurgia; via Cadore 48, 20900. Monza, Italy.

Email: moresco.rosamaria@hsr.it; rosa.moresco@unimib.it

ACTUAL POSITION

Full Professor, Dipartimento di Medicina e Chirurgia, Università degli Studi Milano Bicocca

EDUCATION

1982 Scientific bachelor

1988 Master Degree in Pharmaceutical Chemistry and technology, (108/110), School of Pharmacy, University of Milan

1990 Specialization in Pharmacology (70/70 con lode) University of Milan

CARRIER

1984-1988 Fellow at Institute of Pharmacological Sciences, School of Pharmacy, University of Milan

1988-1989 Fellow: Fondazione Giovanni Lorenzini.

1990-1996 Technician, University of Milan; Centro PET Ciclotrone Ospedale San Raffaele.

1992-1993 Visiting researcher, Centre Hospitalier Frederic Joliot CEA, CNRS. Orsay-Paris, France. Supervisor: Andre Syrota and Bernard Maziere.

1996-2002 Technician, University of Milan and then University of Milan Bicocca at PET Cyclotron-Center, San Raffaele Hospital, Milan.

2002-2011 Researcher, University of Milan Bicocca; Nuclear Medicine Department, San Raffaele Hospital, Milan.

2011-today Head of Preclinical PET Facility, CIS, San Raffaele Hospital-IBFM-CNR, Milan.

2012- 2019 Associate Professor, University of Milan Bicocca

2019 (1 November)- actual Full Professor, University of Milan Bicocca

ATTIVITA' SCIENTIFICA:

Incarichi Istituzionali

2005-2011 Member Directive Board of "Centro di Bioimmagini molecolari, University Milan Bicocca.

2010-actual Board of Directors: "Tecnomed, Fondazione dell'Università degli Studi Milano Bicocca, University Milan Bicocca.

2010-2012 Member of advisory group of AIFA for authorization procedures.

2010-2015 Member of Scientific Technical Committee (CTS) AIFA.

2011-2014 Member Phase I committee, Istituto Superiore di Sanità.

2014-actual Member Directive Board, Milan Center for Neuroscience Neuroscienze di Milano, University Milan Bicocca

2003-actual Associate researcher, National Research Council, INB and then IBFM, Milan, Italy for Preclinical Imaging

2020-actual Coordinator Neuroscience PhD Program, PhD School, University of Milan Bicocca.

Grants

1990 PI CNR project: Cinetica e metabolismo del ^{99m}Tc -CBPAO.

1992 PI CNR project: Valutazione in vivo dei recettori dopaminergici di tipo D2 negli adenomi ipofisari.

1994 PI for CNR CNR-CNRS cooperation projects: "Effetti della concentrazione di dopamina endogena sul legame in vivo di traccianti per i recettori dopaminergici di tipo D2".

2001 PI of Unit Ricerca finalizzata Ministero della Sanità (2001-2004): Valutazione in vivo dei recettori A2 per la adenosina in modelli animali di degenerazione sottocorticale.

2001 PI of Unit: Ricerca finalizzata Ministero della Sanità (2001-2004) ; Valutazione in vivo mediante PET dell'attività dell'acetil colino esterasi nei pazienti affetti da malattia di Alzheimer.

2001 PI of Unit, FIRB-Ministry of University 2001, Determinanti neurobiologici dei disturbi dell'umore e stati di comorbilità con disturbi d'ansia.

2004 PI of Unit PRIN-Ministry of University 2004: Imaging della microglia attivata mediante PET e $[\text{C-11}]\text{PK11195}$.

2004-2009 PI of Unit: European Network of Excellence: EMIL (European Molecular Imaging Laboratories) Project ID: 50356 Funded under: FP6-LIFESCIHEALTH durata: from 2004-07-01 to 2009-06-30.

2005-2010 Membere of Unit: European Network of Excellence Diagnostic molecular imaging (DIMI). Project ID: 512146. FP6-LIFESCIHEALTH. From 2005-04-01 to 2010-09-30

2008 PI of Project AIRC: A molecular imaging approach to evaluate tumor hypoxia in preclinical and clinical studies..from 12 May 2008. (2006-2008)

2008 PI of Project – Minister of Health. Project RFP5-2006-2-342023: "PET molecular imaging as prognostic marker and predictor indicator of response to therapy" da 10/3 2008 a 9/3/2012.

2008 PI of Unit for IBFM-CNR FIRB-MIUR project: Nuove metodologie per Imaging Biomedico. Coordinatore Nazionale. Prof.ssa Maria Carla Gilardi (18/7/2007 a 18/7/2011).

2011-2016 Member of Unit: Imaging of Neuroinflammation in Neurodegenerative Diseases (INMIND); FP/, Large-scale integrating project; EC. Responsabile Prof. Andreas Jacobs University of Munster. Project ID: 278850; FP7-HEALTH . Dal 2012-03-01 al 2017-02-28

2012 P.I. Unit: Progetto Bandiera CNR Nanomax; Funzionalized nanoparticles in the detection and treatment of mammary adenocarcinoma PET/SPECT Imaging and complementary transcriptomic and proteomic approach. (2012-2018)

2013-today Head of Milan IBFM-CNR Node and Scientific Board of JRU. Molecular Imaging Multi Modal Multi Sited Node, Biomedical Imaging Network National Coordinating Person: Prof. Silvio Aime, The European Research Infrastructure for Imaging Technologies in Biological and Biomedical Sciences (Euro-Biolmaging, EuBI or EuBI ERIC).

2013-2017 Membro Unità. Progetto Europeo FP7-HEALTH-2012-INNOVATION-1 INSERT: Development of an integrated SPECT/MRI system for enhanced stratification of brain tumour patients prior to patient-specific radio-chemo therapy and early assessment of treatment efficacy. Responsabile di progetto C Fiorini Politecnico di Milano. Dal 2013-03-01 al 2017-02-28

2013PI of Unit: *CTN01_00177_165430*: Identification, validation and commercial development of new diagnostic and prognostic biomarkers for complex trait diseases). *Parte del Cluster Tecnologico Nazionale Scienze della Vita "ALISEI (2913-2017)*.

2013PI of Unit. PRIN-MIUR. Boosting the generation of authentic striatal DARPP32+ neurons from human pluripotent stem cells for transplantation in Huntington's Disease. Coordinatore Progetto: (2013-2016) .

2014PI of Project: AIRC 2014; Multimodal imaging approach for identification of new potential biomarker for treatment response in glioma models. Responsabile Progetto (2015-2017).

2016 PI of Unit. Ministero della Salute: New strategies for diagnostic, therapeutic and clinical care in Neurologic diseases. Responsabile Progetto: P Dadamo OSR (2016-2018).

2017 PI of Unit: "Alterazioni metaboliche, stress cellulari e processi neurodegenerative - AMANDA Accordo Quadro di collaborazione tra Regione Lombardia e il Consiglio Nazionale delle Ricerche (CNR) sottoscritto l'1 ottobre 2015, il cui schema è stato approvato con DGR n. 3866 dell'17 luglio 2015 (di cui al Decreto regionale n. 3623 del 27 aprile 2016 e s.m.i e decreto di concessione n.7884 del 5 agosto 2016).

2017 PI of Unit. PRIN-MIUR. Generation of functional striatal neurons for brain repair in Huntington Disease Coordinatore Progetto: Prof.ssa Elena Cattaneo. (2017-2020).

Partecipazione at: EU Joint Program - Neurodegenerative Disease Research (JPND) project under the 2016 call "Working Groups for Harmonisation and Alignment in Brain Imaging Methods for Neurodegeneration". (MIUR, MinSal).

2018 Coordinatore Unità Università di Milano PON Bicocca, Progetto "MOLIM ONCOBRAIN LAB - Metodi innovativi di imaging molecolare per lo studio di malattie oncologiche e neurodegenerative".

2019. PI of Project: AIRC: IG 21365 Effetto della metformina come terapia add-on nei gliomi: identificazione di biomarcatori di imaging predittivi di risposta. (2019-2023).

Membro, RoadMap ESFRI: SysBio SysBioNet infrastruttura di ricerca (2013-2016).

2018. PI of Unit. PON-MIUR Project. MOLIM ONCOBRAIN LAB - Metodi innovativi di imaging molecolare per lo studio di malattie oncologiche e neurodegenerative (2018-2021)

2020 PI of Unit: Nevermind, Fondazione Regione Lombardia (2020-2022)

2019- PI of Unit. Immunohub, regione Lombardia (2019-2022)

Invited speaker:

1997 8° Workshop "Farmacologia clinica".Villa Olmo; organizzato dalla la Scuola di Specializzazione in Farmacologia Clinica dell'Università degli Studi di Milano. Villa Olmo, 3-10 Giugno 1997.

1998 XVIII Corso avanzato di Chimica Farmaceutica e seminario nazionale dottorandi" organizzato dalla Divisione di Chimica Farmaceutica della Società Chimica Italiana Urbino, 29 giugno - 3 luglio 1998.

1998 8° Congresso Società Italiana Psichiatria Biologica. Napoli, 29 settembre – 3 ottobre 1998

1998 Scuola di Biofisica "Bioimmagini, dalle molecole all'uomo". Bressanone, 5-8 ottobre 1998.

1999 Gruppo Nazionale di Bioingegneria "Tecnologie e metodologie per le immagini funzionali". Bressanone.

2000 Scientific Exchange program schizophrenia dementia and bipolar disorder – Obsessive, compulsive, disorder. 18-22 giugno Boston.

2001 VI Convegno Nazionale Società Italiana di Psicopatologia (SOPSI). Roma, 21 febbraio-25 febbraio 2001.

2002 Course of Radiochemistry Society"Produzione di radiotraccianti PET". Milano

2002 Course of ISS: "Etica e Radiazioni nella Sperimentazione Clinica". Istituto Superiore di Sanità, Roma

2003 Studi recettoriali nella schizofrenia: dalla ricerca alla clinica. Simposio tematico, VIII Convegno Nazionale Società Italiana di Psicopatologia (SOPSI). Roma, 25 febbraio-1 marzo 2003. 7

2003 XLIII Congresso Società Italiana di Psichiatria. Bologna 2003.

2003 Course of Course of Radiochemistry Society: "Produzione di radiotraccianti PET". Milano

2003 Lessons and seminars at Master in Progettazione e Sviluppo dei farmaci. Facoltà di Chimica Farmaceutica. Università degli Studi di Pavia

2004 ECM program for Azienda Ospedaliera San Gerard – Monza: "La PET in Oncologia" – Monza 18 settembre e 6 Novembre.

2004 Course of Course of Radiochemistry Society: "Produzione di radiotraccianti PET". Milano.

2004 Neuroscience symposium of EANM: "What has neuroimaging learned us about mood disorders". Congresso della Società Europea di Medicina Nucleare, Helsinki. 4-8 settembre 2004.

2004 Advisory Board and invited speaker at Bristol Mayer Squib - Neuroimaging Advisory Board December 3rd, Boston.

2004 Imaging delle patologie psichiatriche mediante PET Vedere l'invisibile. Le tecniche d'Imaging molecolare e la loro applicazione allo studio del Sistema Nervoso, organizzata da CEND (Centro Eccellenza sulle Patologie Neurodegenerative dell'Università di Milano). Milano, 18 Febbraio 2004.

2004 Radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]Zofenoprilat. Gli ACE inibitori nel trattamento delle malattie cardiovascolari. Roma, 11-12 Marzo.

2004 Lesson and seminars Master in Progettazione e Sviluppo dei farmaci. Facoltà di Chimica Farmaceutica. Università degli Studi di Pavia

2006 Longitudinal evaluation of a preclinical model of Huntington disease using molecular imaging techniques. Annual Meeting EMIL/DiMi. Saclay 17 Maggio.

2006 DIMI training course: Molecular imaging in drug discovery. Application in neurology. Milano, 22 Febbraio.

2006 Targeting Adenosine A2A Receptors in Parkinson's Disease and other CNS Disorders; Boston 17-19 Maggio.

2006 Scientific Board "Nuclear Medicine in Oncology: from Basic research to clinical application" L'Aquila, 7 Settembre.

2006 PET for Target Therapy., Sessione PET e terapia e sessione: Imaging Molecolare. VIII Congresso Nazionale AIMN Torino, 20-24 Ottobre.

2007 2°DIMI workshop: Molecular imaging in drug discovery. Milano, 12-13 Febbraio.

2007 Lesson for PhD Course in Translational Medicine, Università degli Studi di Milano, Facoltà di medicina e Chirurgia. Milano, 4-7 Giugno.

2007 Invited speaker at DiMi annual meeting 2007. Napoli 13 Giugno 2007.

2008 XVIII Annual meeting AIMN: Medicina Nucleare e Imaging Molecolare. Roma 29 Febbraio-2 Marzo.

2008 Ricerca innovativa per farmaci più sicuri. CEND. 20 Gennaio

2008 Multidisciplinary Conference: Pisa, 26-30 ottobre.

2009 Dai test in vitro alle misure in vivo 20 Marzo. Quantificazione in Neurologia, Corso pregressuale: Congresso Nazionale AIMN, Firenze 20-24 Marzo

2010 Workshop. Caratterizzazione multidimensionale dei tumori. Programma integrato di oncologia – INT, 8 Giugno.

2010 Prima Conferenza Nazionale sulla Ricerca Sanitaria, Cernobbio - Villa Erba 8 e 9 novembre 2010. Tavole rotonde: le nuove frontiere dell'Imaging; La sfida delle tecnologie avanzate per la diagnosi e la terapia.

2011 Scuola di Dottorato di Ricerca in Oncologia e Oncologia Chirurgica - Università di Padova: 4 Febbraio 2011, Istituto Oncologico Veneto: Imaging molecolare in vivo in ricerca trasazionale.

2011 Ricerca clinica con medicinali sperimentali, tavola rotonda: legislazione e radiofarmaci. X Congresso della Associazione Italiana di Medicina Nucleare; Rimini, 18-21 Marzo.

2011 "Molecular Imaging: from cell to man" Euro-Biolmaging, a largescale pan European research infrastructure project on the European Strategy Forum on Research Infrastructures (ESFRI) Roadmap. Torino 24 Novembre.

2012 Ruolo e compiti della CTS; Corso di perfezionamento: " La gestione dei Medicinali e dei prodotti ad attività salutare: aspetti regolatori; Università degli Studi di Milano.

2011 Ruolo e compiti della CTS; Corso di perfezionamento: " La gestione dei Medicinali: aspetti regolatori; Università degli Studi di Milano.

2012 PET Imaging of Brain Inflammation, XIV Congresso Società Italiana di Neuroscienze, Catania, 19-22 Aprile.

2012 PET imaging of regional tumor hypoxia in pre-clinical research: Approaching tumor biology by preclinical imaging, Bologna 16 Ottobre 2012.

2012 PET based molecular imaging in oncology: focus on radiopharmaceuticals development and validation. Molecular Imaging Conference. Area Science Park Congress Hall. Padriciano. Trieste. 10- 11 Dicembre 2012.

2013 Applicazioni dell'Imaging Molecolare in Oncologia. Società di Chimica Italiana - Gruppo Interdivisionale di Radiochimica. Bertinoro; 24-25 MAGGIO 2013.

2014 Tavola rotonda: la scelta consapevole dei mezzi di contrasto: 46° Congresso Nazionale della Società Italiana di Radiologia Medica - Firenze 22-25 Maggio 2014

2014 "PET Imaging of cancer hallmarks in pre-clinical research, 100° Congresso Nazionale Società Italiana di Fisica; Pisa 22-26 Settembre.

2015. International Workshop on Imaging; September 2015, Varenna, Italy

2015 Dalla registrazione EMA all'entrata in commercio in Italia: quali sono le differenze e perché? In: Il percorso del farmaco dagli studi regolatori all'accesso dei pazienti. Milano, Exposalute; Regione Lombardia, 10 settembre 2015.

2016 Imaging multimodale in vivo in modelli preclinici di malattia del SNC (27 Giugno) INN: Prospettive di Neuroscienze. 27-28 10 Verona. 27 Giugno. Aula Magna "G. De Sandre" - Policlinico "G.B. Rossi" Piazzale Scuro, 10 - 37134 Verona

2016 Il ruolo della sperimentazione clinica "in-house, 6 Maggio, VI congresso nazionale del gruppo interdisciplinare di chimica dei radiofarmaci. Cuneo, 6-7 Maggio.

2016 Il percorso del farmaco in Italia: dall'approvazione EMA alla rimborsabilità. Il percorso del farmaco:dalla scoperta alla clinica. Fondazione IRCCS Policlinico San Matteo 14 aprile 2016.

2016 Relatore e Comitato Scientifico. Central and peripheral markers of Neuroinflammation. 7 Luglio. Second international meeting of the Milan Center for Neuroscience (Neuromi). Prediction and prevention of dementia: new hope Milan, July 6-8, 2016

2016 Master in: Valutazione e gestione delle tecnologie e dei servizi sanitari, Università di Milano Bicocca

2017 Tracking of target expression and drug delivery. Milano, 9 Febbraio. Advanced Immune Bioimaging. UNIVACFLU and IMMUTRAIN joint Symposium (Campus IFOM-IEO, Milan 8-10 Febbraio).

2017 European Radiopharmacy course 2015 (EANM and INSTN). Modulo Radiolabelled antibodies and peptides and Preclinical safety of Radiopharmaceuticals (27-28 Marzo). CEA, Saclay, France.

2017 "Nano-structured probes for PET", 11 Aprile. International School of Nanomedicine Course: "New trends in Nanomedicine" 8-13 APRIL 2017. Erice, Italy

2018 Selected presentation, Imaging metabolism, TOPIM 2018, ESMI.

2019-actual: Lezione a Master nello sviluppo Clinico del farmaco- University di Catania

Research interest:

- In vitro study of dopaminergic receptor modifications present in various preclinical experimental models (alcohol, lead, pharmacological treatment with calcium antagonists).
- Validation and development of kinetic models to be applied in clinical research protocols for the in vivo measurement of biological variables with PET techniques.
- Clinical PET molecular imaging for the study of neurobiology biology of behaviour and for the development of psychoactive drugs.
- Study of the mechanisms of neuronal degeneration with particular reference to the visualization of the activation of microglia cells in preclinical models and in patients suffering from neurodegenerative diseases.
- Application of molecular imaging to the characterization of animal models of neoplastic disease using PET and to the validation of new radiopharmaceuticals of potential diagnostic interest in oncology.
- Molecular PET imaging for the development of new drugs and in the early assessment of response to treatments.

SCIENTIFIC SOCIETIES

1990-2006, 2009-2013 Associazione Italiana di Medicina Nucleare
2005-2006 European Society for Molecular Imaging
2014-oggi European Society for Molecular Imaging
2015-oggi Società Italiana di Farmacologia

EDITORIAL BOARD AND REVISION

Reviewers for: European Journal Nuclear Medicine, Neurobiology of Disease, Journal Medicinal Chemistry, Journal of Affective Disorders, Acta Psychiatrica Scandinavica, Psychological Medicine, Journal Molecular Endocrinology, Neurochemistry International, Future Medicine, Brain, Current Drug Therapy, Journal Neurosciences, Journal Nuclear Medicine, Plos one, Cancers etc. Reviewer for grants: Austrian Science Fund, UNITED STATES - ISRAEL Binational Science Foundation, Wellcome Trust Limited, FISM;- Editorial Board Member of Clinical and Translational Imaging: Reviews in Nuclear Medicine and Molecular Imaging, Springer. - Editorial Board Member of European Journal Nuclear Medicine Molecular Imaging Research, Springer.

TEACHING

Supervisor of more of 50 Master Thesis for student of Biotechnology, Pharmacy and Medicine
Expert for PhD thesis evaluation: Dr. K. Husted Adams della: Facoltà di "Health Sciences", Università di Copenhagen (2004), Caterina Facchin, Università Paris Descartes École doctorale: Médicament, Toxicologie, Chimie, Imageries.
PhD supervisor: 2005-2006 Dott Lucia Pietra, tesi di Dottorato in Tecnologie Biomediche XIX ciclo; Università di Milano Bicocca: "Sviluppo di tecniche di tomografia ad emissione per lo studio della neurochimica cerebrale. Facoltà di Medicina

e Chirurgia, Università degli Studi Milano Bicocca. 2006-2007 Dott. Sara Belloli, tesi di Dottorato in Tecnologie Biomediche. Facoltà di Medicina e Chirurgia, Università degli Studi Milano Bicocca. 2007-2008 Dott. Daniela Rota, tesi di Dottorato in Tecnologie Biomediche-Ciclo. Facoltà di Medicina e Chirurgia, Università degli Studi Milano Bicocca. 2007-2008 Dott. Silvia Valtorta, tesi di Dottorato in Medicina Molecolare XIII. Facoltà di Medicina e Chirurgia, Università degli Studi Milano. 2011-2013 Dott. Elena Andreolli, tesi di Dottorato in Tecnologie Biomediche. Facoltà di Medicina e Chirurgia, Università degli Studi Milano Bicocca. 2018-2020: Tutor Dott.ssa Valentina Murtaj, Tesi di Dottorato in Neuroscienze, Dipartimento di Medicina e Chirurgia, Università degli Studi Milano Bicocca, 2021-actual: Dott. Margherita Tassan, Tesi di Dottorato in Neuroscienze, Dipartimento di Medicina e Chirurgia, Università degli Studi Milano Bicocca
University Courses: Teaching: from 2002-actual: courses of Diagnostic Imaging, Radiopharmacology, Molecular Imaging for the School of Biotechnology, Medicine and Technician of Radiology at University Milan Bicocca.
Speciality School Courses. Courses on Neuroimaging, contrast agent and radiopharmaceuticals and kinetic modeling at the Speciality School of Nuclear Medicine and Neurology.

International or courses : 2014-actual Modulo insegnamento:Biologicals radiopharmaceuticals: focus on peptides & antibody.INSTN-CEA.Desc radiopharmacie et radiobiologie enseignement de l'u.e. radiopharmacie clinique, Saclay, France. 2017-actual Moduli insegnamento: 1)Biologicals radiopharmaceuticals: focus on peptides & antibody; 2)Methods of toxicity assessment of the preparation of radiopharmaceuticals:Meeting regulatory requirements.Desc radiopharmacie et radiobiologie enseignement de l'u.e. radiopharmacie clinique, Saclay.

SCIENTIFIC PAPER (PEER REVIEWED JOURNAL)

1. Govoni S, Di Giovine S, **Moresco RM**, Battaini F, Trabucchi M. Effect of chronic calcium antagonist treatment on dopamine recognition sites in rat striatum. *Neurosci Lett*, 1988; 87: 173-177. **IF 1,967**
2. Lucchi L, **Moresco RM**, Govoni S, Trabucchi M.:Effect of chronic ethanol treatment on dopamine receptors subtypes in rat striatum. *Brain Res*, 1988; 449: 347-351. **IF 2,474**
3. **Moresco RM**, Dall'Olio R, Gandolfi O, Govoni S, Di Giovine S, Trabucchi M. Lead neurotoxicity: a role for dopamine receptors. *Toxicology*, 1988; 53: 315-322. **IF 2,061**
4. Sher E, Pandiella A, **Moresco RM**, Clementi F. Voltage-operated calcium-channel subtypes in human neuroblastoma and rat pheochromocytoma cells. *Ann NY Acad Sci*, 1988; 560: 249-250. **IF 1,892**
5. Lucignani G, **Moresco RM**, and Fazio F. PET-based neuropharmacology: state of the art. *Cereb Brain Metab Rev*, 1989; 1: 271-287.
6. **Moresco RM**, Govoni S, Battaini F, Trivulzio S, Trabucchi M. Omegaconotoxine binding decrease in aged rat brain. *Neurobiol Aging*. 1990; 11: 433-436. **IF 5,552**
7. Fazio F, **Moresco RM**, Landoni C, Rossetti C, Lucignani G. Nuovi radiofarmaci ed imaging dei recettori cardiaci. *Giornale Italiano di Cardiologia*, 1991; 21: 915-917.
8. Schmidt K, Lucignani G, **Moresco RM**, Rizzo G, Gilardi MC, Messa C, Colombo F, Fazio F, and Sokoloff L. Errors introduced by tissue heterogeneity in estimation of local cerebral glucose utilization with current kinetic models of the [18F]Fluorodeoxyglucose method. *J Cerebr Blood F Met*, 1992; 12: 823-834. **IF 5,370**
9. Lucignani G, Schmidt KC, **Moresco RM**, Striano G, Colombo F, Sokoloff L, Fazio F. Measurement of regional cerebral glucose utilization with fluorine-18-FDG and PET in heterogeneous tissues: theoretical considerations and practical procedure. *J Nucl Med*, 1993; 34: 360-369. **IF 4,899**
10. Lucignani G, **Moresco RM**, Fazio F. Tomografia ad emissione di positroni (PET) in farmacocinetica e farmacodinamica. *Bollettino Chimico Farmaceutico*, 1993; 132: 231-233.
11. Turkheimer F, **Moresco RM**, Lucignani G, Sokoloff L, Fazio F, Schmidt K. The use of spectral analysis to determine regional cerebral glucose utilization with positron emission tomography and [18F]Fluorodeoxyglucose: Theory, implementation, and optimization procedures. *J Cerebr Blood F Met*, 1994; 14: 406-422. **IF 5,370**
12. **Moresco RM**, Casati R, Lucignani G, Carpinelli A, Schmidt K, Todde S, Colombo F, and Fazio F. Systemic and cerebral kinetics of 16a [18F]Fluoro-17b-Estradiol: a ligand for the *in vivo* assessment of estrogen receptor binding parameters. *J Cerebr Blood F Met*, 1995; 15: 301-311. **IF 5,370**
13. Monti LD, Lucignani G, Landoni C, **Moresco RM**, Piatti PM, Stefani I, Pozza G, and Fazio F. Myocardial glucose uptake evaluated by Positron Emission Tomography and Fluorodeoxyglucose during hyperglycemic clamp in IDDM patients. Role of free fatty acid and insulin levels. *Diabetes*, 1995; 44: 537-542. **IF 8,292**
14. Loc'h C, Halldin C, Bottlaender M, Swahn CG, **Moresco RM**, Maziere M, Farde L, Mazierte B. Preparation of [76BR]FLB457 and [76BR]FLB463 for examination of striatal and extrastriatal dopamine D2 receptors with PET. *Nucl Med Biol*, 1996; 23: 813-819. **IF 2,000**
15. **Moresco RM**, Scheithauer BW, Lucignani G, Lomardi D, Rocca A, Losa M, Casati R, Giovanelli M, Fazio F. Estrogen receptors in meningiomas: a correlative PET and immunohistochemical study. *Nucl Med Commun*, 1997; 18: 606-615. **IF 1,230**

16. Lucignani G, Losa M, **Moresco RM**, Del Sole A, Matarrese M, Bettinardi V, Mortini P, Giovanelli M, Fazio F. Differentiation of clinically non-functioning pituitary adenomas from meningiomas and craniopharyngiomas by positron emission tomography [18F]Fluoro-ethyl-spiperone. *Eur J Nucl Med*, 1997; 24: 1149-1155. **IF 3,324**
17. Messa C, Volontè MA, Fazio F, Zito F, Carpinelli A, d'Amico A, Rizzo G, **Moresco RM**, Paulesu E, Franceschi M, Lucignani G. Differential distribution of striatal [123I]Cit in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. *Eur J Nucl Med*, 1998; 9: 1270-1276. **IF 3,324**
18. Matarrese M, Soloviev DV, **Moresco RM**, Ferri V, Simonelli P, Magni F, Colombo D, Todde S, Carpinelli A, Fazio F; Galli Kienle M. Synthesis and biodistribution of (R,S)-O-methyl [11C]-1-[3-(5-methoxy-1,2,3,4-tetrahydro-1-naphthalenyl)propyl]-4-phenylpiperazine (PNU-157760), a putative radioligand for 5-HT_{1A} receptors. *Bioorg Chemistry*, 1998; 26: 91-102. **IF 1,288**
19. **Moresco RM**, Loch C, Ottaviani M, Guibert B, Levieil V, Maziere M, Fazio F, Maziere B. Effects of Dopamine on the *in vivo* binding of Dopamine D₂ receptors radioligands in rat striatum. *Nucl Med Biol*, 1999; 26: 91-98. **IF 2,000**
20. Wollmer P, **Moresco RM**, Simonelli P, Matarrese M, Rigamonti M, Ortu G, La Gaetana R, Soloviev D, Galli M, Fazio F. Evaluation of [O-Methyl 11C]fluvoxamine as a tracer for serotonin re-uptake sites. *Nucl Med Biol*, 2000; 27:177-81. **IF 2,000**
21. Matarrese M, Soloviev D, **Moresco R.M.**, Todde S, Simonelli P, Colombo D, Magni F, Carpinelli A, Fazio F, Galli Kienle M, Synthesis and *in vivo* evaluation of 3-[11C]methyl-(3-methoxy-naphthalen)-2-yl-(1-benzyl-piperidin)-4-yl-17 acetate(SB235753) as a putative Dopamine D₄ receptors antagonist for PET. *J Labelled Compd Radiopharm*, 2000; 43: 359-374 **IF 1,207**
22. Todde S, **Moresco R.**, Fröstl W, Stampf P, Matarrese M, Carpinelli A, Magni F, Galli Kienle M and Fazio F. Synthesis and *in vivo* evaluation of [11C]CGP62349, a new GABAB_B receptor antagonist. *Nucl Med Biol*, 2000; 27: 565-569. **IF 2,000**
23. **Moresco RM**, Matarrese M, Soloviev D, Simonelli P, Rigamonti M, Gobbo C, Todde S, Carpinelli A, Galli Kienle M, Fazio F. Synthesis and *in vivo* evaluation of [11C]ICI118551 as a putative subtype selective 2-adrenergic radioligand. *Int J Pharm*, 2000; 204: 101-109. **IF 1,539**
24. **Moresco RM**, Colombo C, Fazio F, Bonfanti A, Lucignani G, Messa C, Gobbo C, Galli L, Del Sole A, Lucca A, Smeraldi E. Effect of Fluvoxamine treatment on the *in vivo* binding of [F-18]FESP in drug naive depressed patients: a PET study. *NeuroImage*, 2000; 12: 452-465. **IF 6,192**
25. Todde S, **Moresco RM**, Simonelli P, Baraldi PG, Cacciari B, Spallato G, Varanid K, Monopoli A, Matarrese M, Carpinelli A, Magni F, Galli-Kienle M and Faziosa F. Design, radiosynthesis and biodistribution of a new potential ligand for the *in vivo* imaging of adenosine A_{2A} receptor using Positron Emission Tomography (PET). *J Med Chem.*, 2000; 43: 4359-4362. **IF 4,820**
26. Zanardi R, Artigas F, **Moresco RM**, Colombo C, Messa C, Gobbo C, Smeraldi E, Fazio F. Increased 5-HT₂ receptor binding in frontal cortex of depressed patients responding to paroxetine treatment: a PET scan study. *J Clin Psychopharmacology*, 2001; 21:53-58. **IF 4,432**
27. Soloviev DV, Matarrese M, Moresco RM, Todde S, Bonasera TA, Sudati F, Simonelli P, Magni F, Colombo D, Carpinelli A, Galli Kienle M, Fazio F. Asymmetric synthesis and preliminary evaluation of (R)- and (S)- [11C]bisoprolol, a putative 1-selective adrenoceptor radioligand. *Neurochem Int*, 2001; 38: 169-180. **IF 3,261**
28. Carpinelli A, Matarrese M, **Moresco RM**, Simonelli P, Todde S, Magni F, Galli Kienle M, Fazio F. Radiosynthesis of [123I]bCIT a selective ligand for the study of the dopaminergic and serotonergic system in human brain. *Appl Radiat Isot*, 2001; 54: 93-95. **IF 0,690**
29. **Moresco RM**, Tettamanti M, Gobbo C, Del Sole A, Ravasi L, Messa C, Paulesu E, Lucignani G, Perani D, Fazio F. Acute effect of 3-(4-acetamido)-butyryl-lorazepam (DDS2700) on brain function assessed by PET at rest and during attentive tasks. *Nucl Med Com*, 2001; 22: 399-404. **IF 1,230**
30. Matarrese M, **Moresco RM**, Cappelli A, Anzini M, Vomero S, Simonelli P, Verza E, Magni F, Sudati F, Soloviev V, Todde S, Carpinelli A, Galli Kienle M, Fazio F. Labelling and evaluation of *N*-[11C]methylated quinoline 2-carboxamides as potential radioligands for visualisation of peripheral benzodiazepine receptors. *J. Med.Chem*, 2001; 44:579-585. **IF 4,820**
31. Moresco R, Messa C, Lucignani G, Rizzo G G, Todde S, Gilardi MC, Grimaldi A, Fazio F. PET in psychopharmacology. *Pharmacol Res*, 2001 ;44:151-159. **IF 1,144**
32. Antonini A, **Moresco RM**, Gobbo C, De Notaris R, Panzacchi A, Barone P, Calzetti S, Negrotti A, Pezzoli G, Fazio F. The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. *Neurol Sci*, 2001; 22:47-48. **IF 0,989 2-s2.0-0036757883**
33. Volonte MA, **Moresco RM**, Gobbo C, Messa C, Carpinelli A, Rizzo G, Comi G, Fazio F. PET study with [11-C]raclopride in Parkinson's disease: preliminary results on the effect of amantadine on the dopaminergic system. *Neurol Sci*, 2001; 22:107-108. **IF 0,989**

34. **Moresco RM**, Volonte' MA, Messa C, Gobbo C, Galli L, Carpinelli A, Rizzo G, Panzacchi A, Franceschi M, Fazio F. New Perspectives on neurochemical effects of Amantadine in the brain of Parkinsonian patients: a PET- [11C]Raclopride study. *J Neural Transmission*, 2002; 109: 1265-1274. **IF 2,512 (18) 2-s2.0-0036390350**
35. **Moresco RM**, Dieci M, Messa C, Gobbo C, Galli L, Rizzo G, Panzacchi A, De Peri L, Invernizzi G, Fazio F. In vivo serotonin 5HT_{2A} receptor binding and personality traits in healthy subjects: a PET study. *NeuroImage*, 2002; 17: 1470-1478. **IF 6,192 (77) 2-s2.0-0036432115**
36. Lucignani G, Gobbo C, **Moresco RM**, Antonini A, Panzacchi A, Bonaldi L, Carpinelli A, Caraceni T, Fazio F. The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using 11C-2-beta-carbomethoxy-3-beta-(4-fluorophenyl)-tropine in patients with movement disorders. *Nucl Med Commun.*, 2002; 23: 1047-1055. **IF 1,230 (18) 2-s2.0-0036854466**
37. Matarrese M, **Moresco RM**, Romeo G, Turolla EA, Simonelli P, Todde S, Belloli S, Carpinelli A, Magni F, Russo F, Galli Kienle M, Fazio F. [11C]RN5: a new agent for the in vivo imaging of myocardial alpha₁-adrenoceptors. *Eur J Pharmacol*, 2002; 453: 231-238. **IF 2,352 (8) 2-s2.0-0037174652**
38. Antonini A, **Moresco RM**, Gobbo C, De Notaris R, Panzacchi A, Barone P, Bonifati V, Pezzoli G, Fazio F. Striatal dopaminergic denervation in early and late onset Parkinson's disease assessed by PET and the tracer [11C]FECIT: preliminary findings in one patient with autosomal recessive parkinsonism (Park2). *Neurol Sci*, 2002;23 Suppl 2: S51-52. **IF 0,989 (13)**
39. Messa C, Colombo C, **Moresco RM**, Gobbo C, Galli L, Lucignani G, Gilardi MC, Rizzo G, Smeraldi E, Zanardi R, Artigas F, Fazio F. 5-HT_{2A} receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. *Psychopharmacology*, 2003; 167: 72-78. **IF 3,420 (76)**
40. Scarrone S, Cappelli A, Cupello A, Matarrese M, Moresco RM and Fazio F. Ethanol Inhibits the Binding of Substance P to Rat Brain Cortex NK1 Receptors. *Neurochemical Research*, 2003; 28: 1159-1162. **IF 1,511 19**
41. Belloli S, **Moresco RM**, Matarrese M, Biella , Sanvito F, Simonelli P, Turolla E, Olivieri S, Cappelli S, Vomero S, Galli-Kienle M and Fazio F. Evaluation of three quinoline-carboxamide derivatives as potential radioligands for the in vivo PET imaging of neurodegeneration. *Neurochem Int*, 2004; 44 (6): 433-440. **IF 3,261**
42. Matarrese M, Salimbeni A, Turolla EA, Turozzi D, **Moresco RM**, Poma D, Magni F, Todde S, Rossetti C, Sciarone MT, Bianchi G, Galli Kienle M, Fazio F. Design, 11C-radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]Zofenoprilat. *Bioorg Med Chem*, 2004 1; 12(3): 603-611. **IF 2,185**
43. Cappelli A, Giuliani G, Pericot Mhor G, Galleli A, Anzini M, Vomero S, Cupello A, Scarrone S, Matarrese M, **Moresco RM**, Fazio F, Finetti F, Morbidelli L, Ziche M. A Non-peptide NK1 receptor agonist showing subpicomolar affinity. *J Med Chem*, 2004; 47 (6): 1315-1318. **IF 4,820**
44. Lucignani G, Panzacchi A, Bosio L, **Moresco RM**, Ravasi L, Coppa I, Chiumello G, Frey K, Koeppe R, Fazio F, GABA_A receptor abnormalities in Prader-Willi syndrome assessed with positron emission tomography and [11C]flumazenil. *Neuroimage*, 2004; 22: 22-28. **IF 6,192**
45. **Moresco RM**, Cavallaro R, Messa C, Bravi D, Gobbo C, Galli L, Lucignani G, Colombo C, Rizzo G, Velonà I, Smeraldi E, Fazio F. Cerebral D₂ and 5HT₅ receptor occupancy in schizophrenic patients treated with olanzapine or clozapine. *J Psychopharmacol*, 2004; 18 (3): 355-365. **IF 2,262**
46. **Moresco RM**, Todde S, Belloli S, Simonelli P, Panzacchi A, Rigamonti M, Galli-Kienle M, Fazio F. In vivo imaging of adenosine A_{2a} receptors in rat and primate brain using [11C]SCH442416. *Eur J Nucl Med Mol I*, 2005; 32(4); 405-413. **IF 3,324**
47. Franceschi M, Anchisi D, Pelati O, Zuffi M, Matarrese M, **Moresco RM**, Fazio F and Perani D. Glucose metabolism and serotonin receptors distribution in the frontotemporal lobe degeneration. *Ann Neurol*, 2005; 57 (2): 216-225. **IF 7,717**
48. Tettamanti M, Moro A, Messa C, **Moresco RM**, Rizzo G, Carpinelli A, Matarrese M, Fazio F. Basal ganglia and language: Phonology modulates dopaminergic release. *Neuroreport*, 2005; 16: 397-401. **IF 2,503**
49. Moresco RM, Fazio F. Molecular imaging of individual behaviour. *Eur J Nucl Med Mol Imaging*. 2005; Jun;49(2):205-14. **IF 3, 324 (1)**
50. Colabufo NA, Berardi F, Contino M, Fazio F, Matarrese M, **Moresco RM**, Niso M, Perrone R, Tortorella V. Distribution of sigma receptors in EMT-6 cells: Preliminary biological evaluation of PB167 and potentials for *in vivo* PET. *Journal of Pharmacy and Pharmacology*, 2005; 11:1453-9. **IF 1.340**
51. Turolla EA, Matarrese M, Belloli S, **Moresco RM** Simonelli P, Todde S, Fazio F.. 11C-Labeling of N-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]arylcarboxamide Derivatives and Evaluation as Potential 20 Radioligands for PET imaging of Dopamine D₃ Receptors.: *J Medicinal Chemistry*, 2005; 48:7018-23. **IF 4.82**
52. **Moresco RM**, Fazio F. SPET in psychopharmacology. *Q J Nucl Med Mol Imaging*. 2005 Jun;49(2):205-14
53. Cortelli P, Perani D, Montagna P, Davide Anchisi D, Gallassi R, Morreale A, Provini F, Avoni P, Beelke M, Ferrillo F, **Moresco RM**, Fazio F, Parchi P, Baruzzi A, Lugaresi E, Gambetti P. Pre-symptomatic diagnosis in Fatal Familial Insomnia: serial neurophysiological and [18F] FDG PET studies. Accepted – 2006; *Brain*. 2006; Mar;129:668-75. Epub 2006 Jan 6. **I.F.7.535**

54. Cappelli A, Matarrese M, **Moresco RM**, Valenti S, anziani M, Vomero S, Turolla E, Belloli S, Simonelli P, Filannino A, Lecchi M, Fazio F. Synthesis, labeling, and biological evaluation of halogenated 2-quinolinecarboxamides as potential radioligands for the visualization of peripheral benzodiazepine receptors. *Bioorganic and medicinal chemistry*. 2006;14:4055-66. Epub 2006 Feb 21. **I.F. 2.018**
55. **Moresco RM**, Matarrese M and Fazio F. PET and SPET molecular imaging: focus on serotonin system. *Current Topic in Medicinal Chemistry*. 2006; 6:2027-34. **I.F. 4.400**.
56. **Moresco RM**, Pietra L, Henin M, Panzacchi A, Locatelli M, Bonaldi L, Carpinelli A, Gobbo C, Bellodi L, Perani D, Fazio F. Fluvoxamine treatment and D2 receptors: a PET study on OCD drug naïve patients. *Neuropsychopharmacology*. 2007; 32:197-205. Epub 2006 Oct 4. **I.F. 5.369**
57. Perani D, Garibotto V, Panzacchi A, **Moresco RM**, Orтели P, Corbo M, Fazio F and Folli F. PET evidence of central GABAergic changes in Stiff-Person Syndrome. *Movement Disorders*. 2007 May 15;22(7):1030-3. 2007 **I.F. 3.323**
- 58 Schiffmann SN, Fisone G, **Moresco RM**, Cunha RA, Ferré S. Adenosine A2A receptors and basal ganglia physiology. *Prog Neurobiology*. 2007 Dec;83(5):277-92. **I.F. 11.789**.
59. Filannino MA, Matarrese M, Turolla EA, Masiello V, **Moresco RM**, Todde S, Verza E, Magni F, Cattaneo A, Bachi A, Kienle MG, Fazio F. Synthesis and carbon-11 labeling of (R)- and (S)-Thionisoxetine, norepinephrine reuptake inhibitors, potential radioligands for Positron Emission Tomography. *Applied Radiation and Isotopes. Appl Radiat Isot*. 2007 Nov;65(11):1232-9. **I.F. 0.924**
- 60 Ottobriani L, Ciana P, **Moresco RM**, Lecchi M, Belloli S, Martelli C, Fazio F, Gambhir SS, Maggi A, Lucignani G. Development of a bicistronic vector for multimodality imaging of estrogen receptor activity in a breast cancer model: preliminary application. *E J Nucl Med & Mol Im*. 2008 Feb;35(2):365-78. **I.F. 4.986**
- 61 **Moresco RM**, Lavazza T, Belloli S, Lecchi M, Pezzola A, Todde S, Matarrese M, Carpinelli A, Turolla E, Zimarino V, Popoli P, Malgaroli A and Fazio F. Quinolinic acid induced neurodegeneration in the striatum: a combined *in vivo* 21 and *in vitro* analysis of receptor changes and microglia activation. *E J Nucl Med & Mol Im*. 2008 Apr;35(4):704-15. **I.F. 4.986**
- 62 Panzacchi A, **Moresco RM**, Antonini A, Gobbo C, Isaias UI, Goldwurm S, Bonaldi L, Carpinelli A, Pezzoli G, Fazio F, Perani D. Voxel-based PET study of Dopamine Transporters in Parkinson's Disease: Relevance of Age at Onset. *Neurobiology of Diseases*. 2008 Jul;31(1):102-9. **I.F. 4.128**
- 63 Cappelli A., Mancini A., Sudati F., Valenti S, Anziani M, Belloli S, **Moresco R.M.**; Matarrese M., Vaghi M, Fabro A. Fazio F., Vomero S. Synthesis and Biological Characterization of Novel 2-Quinolinecarboxamide Ligands of the Peripheral Benzodiazepine Receptors Bearing Technetium-99m or Rhenium. *Bioconjugate Chemistry* 2008; Jun;19(6):1143-53; May 30. [Epub ahead of print]. **I.F. 4.384**.
- 64 Perani D, Garibotto V, Gorini A, **Moresco RM**, Henin M, Panzacchi A, Matarrese M, Carpinelli A, Bellodi L, Fazio F. In vivo PET study of 5HT2A serotonin and D2 dopamine dysfunction in drug-naïve obsessive-compulsive disorder. *NeuroImage*. 2008. Aug 1;42(1):306-14. **I.F. 5.559**
- 65 Visigalli I, **Moresco RM**, Belloli S, Politi L, Gritti A, Ungano D, Matarrese M, Turolla Falini A, Scotti G, Naldini L Fazio F, and Biffi A. Monitoring disease evolution and treatment response in lysosomal disorders by the peripheral benzodiazepine receptor ligand PK11195. *Neurobiology of Disease*. 2009 Apr;34(1):51-62. **I.F. 4.128**
- 66 Belloli S, Jachetti E, **Moresco RM**, Picchio M, Lecchi M, Valtorta S, Freschi M, Hess Nichelini R, Bellone M and Fazio F. Characterization of preclinical models of prostate cancer using PET based molecular imaging. *EJNM*. 2009 Aug;36(8):1245-55. **I.F. 4.986**
- 67 Lecchi M, Belloli S, **Moresco RM**, Lui R, Fazio F, Lucignani G. Technical and methodological issues in preclinical imaging with PET and SPET. *Minerva Biotecnologica*. 2009 21 (2), pp. 123-134.
- 68 Cottone L, Valtorta S, Capobianco A, Belloli S, Rovere-Querini P, Fazio F, Manfredi A, **Moresco RM**. Evaluation of the role of tumor-associated macrophages in an experimental model of peritoneal carcinomatosis using [18F]-FDG-PET. *J Nucl Med* 2011 52:1770-1777. **I.F. 6.424**
- 69 Chiaradonna F, **Moresco RM**, Airoldi C, Gaglio D, Palorini R, Nicotra F, Messa C, Alberghina L. From cancer metabolism to new biomarkers and drug targets. *Biotechnol Adv*. 2012 Jan;30(1):30-51. Epub 2011 Jul 23. **I.F. 7.600**
- 70 Zambelli V, Di Grigoli G, Scanziani M1, Valtorta S, Amigoni M, Belloli S, Messa C, Pesenti A, Fazio F, Bellani G, **Moresco RM**. Time course of metabolic activity and cellular infiltration in a murine model of acid-induced lung injury. *Intensive Care Medicine*. *Intensive Care Med*. 2012 Apr;38(4):694-701. Epub 2012 Jan 26. **I.F. 4.996**. 22 71 Re F, **Moresco RM**, Masserini M. Nanoparticles for neuroimaging. *J PhysD: Applied Physics*. 2012 Vol. 45, Issue 7, article id. 073001, 12 pp.) **I.F. 2.109**.
- 72 Marcone A, Garibotto V, **Moresco RM**, Florea I, Panzacchi A, Carpinelli A, Virta JR, Tettamanti M, Borroni B, Padovani A, Bertoldo A, Herholz K, Rinne JO, Cappa SF, Perani D. [11C]-MP4A PET Cholinergic Measurements in Amnesic Mild Cognitive Impairment, Probable Alzheimer's Disease, and Dementia with Lewy Bodies: A Bayesian Method and Voxel-Based Analysis. *J Alzheimers Dis*. 2012; 31(2):387-99. **I.F. 4.261**.
- 73 Jacobs AH, **Tavittian B.** and the PI of the INMIND consortium. Noninvasive molecular imaging of neuroinflammation. *J Cereb Blood Flow Metab*. **J Cereb Blood Flow Metab**. 2012 Jul;32(7):1393-415. **I.F. 4.522**.

- 74 Iannaccone S, MD, Cerami C, Alessio M, Garibotto V, MD, Panzacchi A, Olivieri S, Gelsomino G, **Moresco RM**, Perani D. *In vivo* microglia activation in very early dementia with Lewy Bodies, comparison with Parkinson's Disease. *Parkinsonism & Related Disorders*. 2013; 19: 47-52. **I.F. 3.245**.
- 75 Alberghina L, Gaglio D, Gelfi C, **Moresco RM**, Mauri G, Bertolazzi P, Messa C, Gilardi MC, Chiaradonna F and Vanoni M. Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodeling. *Front Physiol*. 2012; 3:362.
- 76 Grosso E, López M, Salvatore C, Gallivanone F, Di Grigoli G, Valtorta S, **Moresco R**, Gilardi MC, Ramírez J, Górriz JM, Castiglioni I. A Decision Support System for the assisted diagnosis of brain tumors: a feasibility study for 18F-FDG PET preclinical studies. *Conf Proc IEEE Eng Med Biol Soc*. 2012;2012:6255-8.
- 77 Alberghina L, Gaglio D, **Moresco RM**, Gilardi MC, Messa C, Vanoni M. A Systems Biology Road Map for the Discovery of Drugs Targeting Cancer Cell Metabolism. *Curr Pharm Des*. 2014;20(15):2648-66. **I.F. 3.288**
- 78 Valtorta S, Belloli S, Sanvito F, Masiello V, Di Grigoli G, Monterisi V, Fazio F, Picchio M and **Moresco RM**. Comparison of 18F-Fluoroazomycin-Arabinofuranoside and 64Cu-Diacetyl-Bis(N4-Methylthiosemicarbazone) in Preclinical Models of Cancer. *J Nucl Med*. 2013 Jul;54(7):1106-12. **I.F. 5.774**
- 79 Beltrami E, Valtorta S, **Moresco R**, Marcu R, Belloli S, Fassina A, Fazio F, Pelicci P, Giorgio M. The p53-p66Shc Apoptotic Pathway is Dispensable for Tumor Suppression whereas the p66Shc-generated Oxidative Stress Initiates Tumorigenesis. *Curr Pharm Des*. 2013;19(15):2708-14. **I.F. 3.311**
- 80 Sciorati C; Staszewsky L; Zambelli V; Salio M; Di Grigoli G; **Moresco RM**; Clementi E; Russo I; Latini R; Novelli D. Ibuprofen plus Isosorbide Dinitrate Treatment in mdx mice reduces dystrophic heart damage. *Pharmacol Res*. 2013 Jul;73:35-43. **I.F. 4.346 23**
- 81 Garibotto V, Tettamanti M, Marcone A, Florea I, Panzacchi A, **Moresco R**, Virta JR, Rinne J, Cappa SF, Perani D. Cholinergic activity correlates with reserve proxies in Alzheimer's disease. *Neurobiol Aging*. 2013 Nov;34(11):2694.e13-8. **I.F. 6.166**
- 82 Belloli S., Brioschi A, Politi LS, Ronchetti F, Calderoni S, Raccagni I, Pagani A, Monterisi C, Zenga F, Zara G, Fazio F, Mauro A, **Moresco RM**. Characterization of biological features of a rat F98 GBM model: A PET-MRI study with [18F]FAZA and [18F]FDG. *Nucl Med Biol* 2013 Aug;40(6):831-40. **I.F. 2.408**
- 83 Lo Dico A., Valtorta S., Martelli C. Belloli S., Gianelli U., Tosi D., Bosari S., Degrossi A., Russo M., Todde S., Monterisi C., Lucignani G., **Moresco R.M** and Ottobriani L. Validation of an engineered cell model for in vitro and in vivo hypoxia evaluation by different imaging modalities. *Mol Imaging Biol*. 2014 Apr;16(2):210-23. **I.F. 2.869**
- 84 Valtorta S., Nicolini G, Tripodi F, Meregalli C, Cavaletti G, Avezza F, Crippa L., Bertoli G., Fusi P, Pagliarin R, Orsini F, **Moresco RM** and Coccetti P. A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer. *Invest New Drugs* 2014 Dec;32(6):1123-33. **I.F. 2.927**
- 85 Agnusdei V, Minuzzo S, Frasson C, Grassi A, Axelrod F, Satyal S, Gurney A, Hoey T, Segnanfreddo E, Basso G, Valtorta S, **Moresco R**, Amadori A, Indraccolo S. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. *Leukemia*. 2014 Feb;28(2):278-88. **I.F. 10.164**
- 86 Curtarello M, Zulato E, Nardo G, Valtorta S, Guzzo G, Rossi E, Esposito G, Msaki A, Pastò A, Rasola A, Persano L, Ciccarese F, Bertorelle R, Todde S, Plebani M, Schroer H, Walenta S, Mueller-Klieser W, Amadori A, **Moresco RM**, Indraccolo S. VEGF-Targeted Therapy Stably Modulates the Glycolytic Phenotype of Tumor Cells. *Cancer Res*. 2015 Jan 1;75(1):120-33. **I.F. 9.284**
- 87 Lo Dico A, Martelli C, Valtorta S, Raccagni I, Diceglie C, Belloli S, Gianelli, U, Vaira V, Politi LS, Bosari S, Lucignani G, **Moresco RM**, Ottobriani L. Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model. *Eur J Nucl Med Mol Imaging*. 2015 Mar 27. **IF 5,217**.
- 88 Di Grigoli G, Monterisi C, Belloli S, Masiello V, Politi L, Valenti S, Paolino M, Anzini M, Matarrese M, Cappelli A, **Moresco R M**. "Radiosynthesis and preliminary biological evaluation of [18F]VC701, a radioligand for Translocator Protein". *Molecular Imaging. Mol Imaging*. 2015;14.
- 89 Grecchi E, Veronese M, **Moresco RM**, Bellani G, Pesenti A, Messa C, Bertoldo A. Quantification of dynamic [18F]FDG PET studies in acute lung injury. *Imaging and Biology*. 2016 Feb;18(1):143-52. 2015. **IF: 2.774**
- 24
- 90 Cottone L, Capobianco A, Gualteroni C, Monno A, Raccagni I, Valtorta S, Canu T, Di Tomaso T, Lombardo A, Esposito A, Moresco RM, Maschio AD, Naldini L, Rovere-Querini P, Bianchi ME, Manfredi AA. Leukocytes recruited by tumor-derived HMGB1 sustain peritoneal carcinomatosis. *Oncoimmunology*. 2016 Jan 8;5(5):e1122860. **IF 6.266**
- 91 Valtorta S, Moro M, Prinszano G, Bertolini G, Tortoreto M, Raccagni I, Pastorino U, Roz L, Sozzi G, Moresco RM. Metabolic Evaluation of Non-Small Cell Lung Cancer Patient-Derived Xenograft Models Using 18F-FDG PET: A Potential Tool for Early Therapy Response. *J Nucl Med*. 2017 Jan;58(1):42-47. **IF 6,64**
- 92 Mezzapelle R, Rrapaj E, Gatti E, Ceriotti C, Marchis FD, Preti A, Spinelli AE, Perani L, Venturini M, Valtorta S, Moresco RM, Pecciarini L, Doglioni C, Frenquelli M, Crippa L, Recordati C, Scanziani E, de Vries H, Berns A, Frapolli R, Boldorini R, D'Incalci M, Bianchi ME, Crippa MP. Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells. *Sci Rep*. 2016 Mar 10;6:22850. **IF 5.578**

- 93 Gaglio D, Valtorta S, Ripamonti M, Bonanomi M, Damiani C, Todde S, Negri AS, Sanvito F, Mastroianni F, Di Campli A, Turacchio G, Di Grigoli G, Belloli S, Luini A, Gilardi MC, Colangelo AM, Alberghina L, **Moresco RM**. Divergent in vitro/in vivo responses to drug treatments of highly aggressive NIH-Ras cancer cells: a PET imaging and metabolomics-mass-spectrometry study. *Oncotarget*. 2016 Aug 9;7(32):52017-52031. **IF 5.008**
- 94 Faedo A, Laporta A, Segnali A, Galimberti M, Besusso D, Cesana E, Belloli S, **Moresco RM**, Tropiano M, Fuca E, Wild S, Bosio A, Vercelli AE, Biella G, Cattaneo E. Differentiation of human telencephalic progenitor cells into MSNs by inducible expression of Gsx2 and Ebf1. *Proc Natl Acad Sci U S A*. 2017 Feb 14;114(7):E1234-E1242. **IF 9.423**.
- 95 Gargiulo S, Coda AR, Panico M, Gramanzini M, **Moresco RM**, Chalon S, Pappata S. Molecular imaging of neuroinflammation in preclinical rodent models using positron emission tomography. *Q J Nucl Med Mol Imaging*. 2017 Mar;61(1):60-75. **IF 2.413**
- 96 Belloli S, Pannese M, Buonsanti C, Maiorino C, Di Grigoli G, Carpinelli A, Monterisi C, **Moresco RM**, Panina-Bordignon P. Early upregulation of 18-kDa translocator protein in response to acute neurodegenerative damage in TREM2-deficient mice. *Neurobiol Aging*. 2017 Jan 17 [Epub ahead of print]. **IF 5.153**
- 97 Iaccarino L, **Moresco RM**, Presotto L, Bugiani O, Iannaccone S, Giaccone G, Tagliavini F, Perani D. An In Vivo (11)C-(R)-PK11195 PET and In Vitro Pathology Study of Microglia Activation in Creutzfeldt-Jakob Disease. *Mol Neurobiol*. 2017 Apr 28. Epub. **IF 5.397 25**
- 98 Caminiti SP, Presotto L, Baroncini D, Garibotto V, **Moresco RM**, Gianolli L, Volonte MA, Antonini A, Perani D. Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease. *Neuroimage Clin*. 2017 Mar 27;14:734-740. **IF 5.150**
- 99 Rainone P, Riva B, Belloli S, Sudati F, Ripamonti M, Verderio P, Colombo M, Colzani B, Gilardi MC, **Moresco RM**, Prosperi D. Development of 99mTc-radiolabeled nanosilica for targeted detection of HER2-positive breast cancer. *International Journal of Nanomedicine*. 2017 May 2; 12: 3447—3461. <https://doi.org/10.2147/IJN.S129720>. **IF 4.320**
- 100 Corti A, Gasparri AM, Ghitti M, Sacchi A, Sudati F, Fiocchi M, Buttiglione V, Perani L, Gori A, Valtorta S, **Moresco RM**, Pastorino F, Ponzoni M, Musco G, and Curnis F. Glycine N-Methylation in NGR-Tagged Nanocarriers Prevents Isoaspartate Formation and Integrin Binding without Impairing CD13 Recognition and Tumor Homing. *Adv. Funct. Mater*. 2017, 1701245. **IF 13.325**
- 101 Incerti E, Mapelli P, Fallanca F, Bettinardi, V. ; Gianolli, L.; Picchio, M. ; Vuozzo, M. ; Monterisi, C. ; Moresco, R.M. Clinical PET imaging of tumour hypoxia in lung cancer. *Clinical and Translational Imaging*, 1 October 2017, 5(5):473-485).
- 102 Raccagni I, Valtorta S, Belloli S, **Moresco RM**. Tumour hypoxia: lessons learnt from preclinical imaging. *Clinical and Translational Imaging*, 1 October 2017, 5(5):473-485).
- 103 Bellelli G, **Moresco RM**, Panina P, Arosio B, Gelfi C, Morandi A and Cesari M. Is delirium the cognitive harbinger of frailty in older adults? A review about the existing evidence. *Frontiers Medicine*. 2017;4:188. **IF 3.421**
- 104 Putzu A, Valtorta S, Di Grigoli G, Haenggi M, Belloli S, Malgaroli A, Gemma M, Landoni G, Beretta L, **Moresco RM**. Regional Differences in Cerebral Glucose Metabolism After Cardiac Arrest and Resuscitation in Rats Using [(18)F]FDG Positron Emission Tomography and Autoradiography. *Neurocrit Care*. 2018;28(3):370-378. **IF 2.790**
- 105 Valtorta S, Dico AL, Raccagni I, Gaglio D, Belloli S, Politi LS, Martelli C, Diceglie C, Bonanomi M, Ercoli G, Vaira V, Ottobrini L, **Moresco RM**. Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models. *Oncotarget*. 2017 Dec 6;8(68):113090-113104. **IF 4.790**
- 106 Belloli S, Zanotti L, Murtagh V, Mazzone C, Di Grigoli G, Monterisi C, Masiello V, Iaccarino L, Cappelli A, Poliani PL, Politi LS, **Moresco RM**. (18)F-VC701-PET and MRI in the in vivo neuroinflammation assessment of a mouse model of multiple sclerosis. *J Neuroinflammation*. 2018 Feb 5;15(1):33. **IF 5.193**
- 107 Ricciardiello F, Votta G, Palorini R, Raccagni I, Brunelli L, Paiotta A, Tinelli F, D'Orazio G, Valtorta S, De Gioia L, Pastorelli R, **Moresco RM**, La Ferla B and Chiaradonna F. Inhibition of the Hexosamine Biosynthetic Pathway by targeting PGM3 causes breast cancer growth arrest and apoptosis. *Cell Death Dis*. 2018;9(3):377. **IF 5.959**
- 108 Turolla EA, Valtorta S, Bresciani E, Fehrentz JA, Giuliano L, Stucchi S, Belloli S, Rainone P, Sudati F, Rizzi L, Molteni L, Verdì P, Martinez J, Torsello A, **Moresco RM**, Todde S. Study of the Tissue Distribution of TLQP-21 in Mice Using [(18)F]JMV5763, a Radiolabeled Analog Prepared via [(18)F]Aluminum Fluoride Chelation Chemistry. *Front Pharmacol*. 2018 Nov 13;9:1274. **IF 4.400**
- 109 Raccagni I, Belloli S, Valtorta S, Stefano A, Presotto L, Pascali C, Boggi A, Tortoreto M, Zaffaroni N, Daidone MG, Russo G, Bombardieri E, **Moresco RM**. [(18)F]FDG and [(18)F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer. *PLoS One*. 2018 May ;13(5):e0197754. **IF 2.740**
- 110 Perani D, Iaccarino L, Lammertsma AA, Windhorst AD, Edison P, Boellaard R, Hansson O, Nordberg A, Jacobs AH; IMBI Project. A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies. *Alzheimers Dement*. 2019 Aug;15(8):1081-1103.
- 111 Lo Dico A, Valtorta S, Ottobrini L, **Moresco RM**. Role of Metformin and AKT Axis Modulation in the Reversion of Hypoxia Induced TMZ-Resistance in Glioma Cells. *Front Oncol*. 2019 May 31;9:463. **IF 4.848**

- 112 Perani D, Iaccarino L, Jacobs AH; IMBI Brain Imaging Working Group. Application of advanced brain positron emission tomography-based molecular imaging for a biological framework in neurodegenerative proteinopathies. *Alzheimers Dement (Amst)*. 2019 Apr 16;11:327-332.
- 113 Musazzi L, Sala N, Tornese P, Gallivanone F, Belloli S, Conte A, Di Grigoli G, Chen F, Ikin A, Treccani G, Bazzini C, Castiglioni I, Nyengaard JR, Wegener G, Moresco RM, Popoli M. Acute Inescapable Stress Rapidly Increases Synaptic Energy Metabolism in Prefrontal Cortex and Alters Working Memory Performance. *Cereb Cortex*. 2019 Dec 17;29(12):4948-4957. **IF 6.308**
- 114 Murtaç V, Belloli S, Di Grigoli G, Pannese M, Ballarini E, Rodriguez-Menendez V, Marmiroli P, Cappelli A, Masiello V, Monterisi C, Bellelli G, Panina-Bordignon P, Moresco RM. Age and Sex Influence the Neuro-inflammatory Response to a Peripheral Acute LPS Challenge. *Front Aging Neurosci*. 2019 Nov 5;11:299. **IF 4.504**
- 115 Carpinelli A, Rainone P, Belloli S, Reale A, Cappelli A, Germano G, Murtaç V, Coliva A, Di Grigoli G, Valeri A, Gilardi MC, Gianolli L, Anzini M, Moresco RM. Radiosynthesis and Preclinical Evaluation of (11)C-VA426, a Cyclooxygenase-2 Selective Ligand. *Contrast Media Mol Imaging*. 2019 Sep 24;2019:5823261. **IF 1.984**
- 116 Besusso D, Schellino R, Boido M, Belloli S, Parolisi R, Conforti P, Faedo A; Cernigoi M, Campus I, Laporta A, Dickinson Bocchi V, Murtaç V, Parmar M, Spaiardi P, Talpo F, Maniezzi C, Toselli MG, Biella G, Moresco RM, Vercelli A, Buffo A,* and Cattaneo E. Stem cell derived human striatal progenitors innervate striatal targets and alleviate sensorimotor deficit in a rat model of Huntington Disease. *Stem Cell Reports*. 2020;14(5):876-891. **IF 5.499**
- 117 Belloli S, Morari M, Murtaç V, Valtorta S, Moresco RM, Gilardi MC. Translation imaging in Parkinson's disease: focus on neuroinflammation *Frontiers in Aging Neuroscience* Sara Belloli, Michele Morari, Valentina Murtaç, Silvia Valtorta, Rosa Maria Moresco, Maria Carla Gilardi. *Front Aging Neurosci*. 2020;12:152. Published 2020 Jun 5. **IF 4.504**
- 118 Valtorta S, Salvatore D, Rainone P, Belloli S, Bertoli G, Moresco RM. Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance. *Int J Mol Sci*. 2020;21(16):5631. Published 2020 Aug 6. **IF 4.556**
- 119 Gaglio D, Bonanomi M, Valtorta S, Bharat R, Ripamonti M, Conte F, Fiscon G, Righi N, Napodano E, Papa F, Raccagni I, Parker SJ, Cifola I, Camboni T, Paci P, Colangelo AM, Vanoni M, Metallo CM, Moresco RM and Alberghina L. Disruption of redox homeostasis for combinatorial drug efficacy in K-Ras tumors revealed by metabolic connectivity profiling. Accepted September 2020 in *Cancer & Metabolism*. **IF 5.033**
- 120 D'Adamo P, Horvat A, Gurgone A, Mignogna ML, Bianchi V, Masetti M, Ripamonti M, Taverna S, Velebit J, Malnar M, Muhić M, Fink K, Bachi A, Restuccia U, Belloli S, Moresco RM, Mercalli A, Piemonti L, Potokar M, Bobnar ST, Kreft M, Chowdhury HH, Stenovec M, Vardjan N, Zorec R. Inhibiting glycolysis rescues memory impairment in an intellectual disability Gdi1-null mouse. *Metabolism*. 2020 Dec 10;116:154463. **IF 8,60**
- 121 Foray C, Valtorta S, Barca C, Winkler A, Roll W, Müther M, Wagner S, Gardner ML, Hermann S, Schäfers M, Grauer OM, Moresco RM, Zinnhardt B, and Jacobs AH. Imaging temozolomide-induced changes in the myeloid glioma microenvironment. Accepted September 2020 in *Theranostics*. **IF 8.779**
- 122 Rainone P, De Palma A, Sudati F, Roffia V, Rigamonti Valentina, Salvioni L, Colombo M, Ripamonti M, Spinelli A, Mazza D, Mauri P, **Moresco RM**, Prosperi D and Belloli S. 99mTc-radiolabeled silica nanocarriers for targeted detection and treatment of HER2-positive breast cancer. *International Journal of Nanomedicine*. 2021; 16:1943-1960. **IF 4.471**
- 123 Valtorta S*, Lo Dico A, Raccagni I, Martelli C, Pieri V, Rainone P, Todde S, Zinnhardt B, De Bernardi E, Coliva A, Politi L, Viel T, Jacobs AH, Galli R, Ottobri L, Vaira V and R M Moresco, Title "Imaging metformin efficacy as add-on therapy in cells and mouse models of human EGFR glioblastoma", accepted in *Frontiers in Oncology-Neuro-Oncology and Neurosurgical Oncology* April 2021. **IF 4.416**
- 124 Moriggi M, Belloli S, Barbacini P, Murtaç V, Torretta E, Chaabane L, Canu T, Penati S, Malosio ML, Gelfi C, Moresco RM, Esposito A and Daniele Capitano. Skeletal Muscle Proteomic Profile Revealed Gender-related Metabolic Responses in a Diet-Induced Obesity Animal Model. *International journal of Molecular Sciences*. April 2021. **IF 4.55**
- 125 D'Adamo P, Mignogna ML, Musardo S, Ranieri G, Gelmini S, Espinosa P, Marra P, Belloli S, Murtaç V, Moresco RM, and Bellone C. RAB39B-mediated trafficking of the GluA2-AMPA subunit controls dendritic spine maturation and intellectual disability-related behaviour. *Molecular Psychiatry*. 2021. May 25. **IF 12.384**
- 126 Giordani A, Menziani MC, Moresco RM, Matarrese M, Paolino M, Saletti M, Giuliani G, Anzini M, Cappelli A. Exploring translocator protein (TSPO) medicinal chemistry: an Discovery and development of VC701, a promising PET radiotracer for neurodegeneration approach for targeting radionuclides and boron atoms to mitochondria. Accepted *JMC* June 2021. **IF 6.205**
- 127 Gilardi M, Bersini S, Valtorta S, Proietto M, Crippa M, Boussommier-Calleja A, Labelle M, Moresco RM, Vanoni M, Kamm RD, Moretti M. The driving role of the Cdk5/Tln1/FAK^{S732} axis in cancer cell extravasation dissected by human vascularized microfluidic models. *Biomaterials*. 2021 Sep 27;120975. **IF 12.479**
- 128 Valtorta S, Toscani D, Chiu M, Sartori A, Coliva A, Brevi A, Taurino G, Grioni M, Ruffini L, Vacondio F, Zanardi F, Bellone M, Moresco RM, Bussolati O, Giuliani N. [18F](2S,4R)-4-Fluoroglutamine as a new Positron Emission Tomography tracer in Myeloma. *Front Oncol*. 2021 Oct 12;11:760732. **IF 6.244**

129 Novello S, Mercatelli D, Albanese F, Domenicale C; Brugnoli A; D'Aversa E, Vantaggiato S, Dovero S, Murtaç V , Presotto L, Borgatti M, Shimshek D, Bezard E, Moresco RM , Belloli S, Morara M. In vivo susceptibility to energy failure, parkinsonism and LRRK2 kinase activity. Accepted December 2021. Neurobiology of Disease. **I.F. 5,996**.

130 Guarnaccia L, Marfia G, Masseroli MM, Navone SE, Balsamo M, Caroli M, Valtorta S, Moresco RM, Campanella R, Garzia E, Riboni L, Locatelli M. Frontiers in Anti-Cancer Drug Discovery: Challenges and Perspectives of Metformin as Anti- Angiogenic Add-On Therapy in Glioblastoma. Cancers (Basel). 2021 Dec 27;14(1):112. **I.F. 6,12**

HI Scopus: 31, citations: 3487; Google Scholar: HI 36; citation: 4721. IF total: 514,85; IF mean: 4,0

Milan 22/2/2022

R. Moresco